A NEJM article explains how drug prices could decrease.
Top EMA and national authority draw the attention to what is perceived to be the growing problem of high drug prices and suggest several European regulatory means by which the prices of drugs could be decreased
The authors note that, although drug regulators are involved primarily with assessment of quality, safety and efficacy, regulators also have to facilitate access to effective and safe treatment.
The full article is available in open access in the NEJM here.
